Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy.

Secondary Outcomes Blood Ammonia Level Patients in 12 included RCTs who received rifaximin ( n = 371) were observed lower blood ammonia levels in comparison to patients who received other active drugs ( n = 365, nonabsorbable disaccharides and other antibiotics), although the difference did not reach statistical significance (WMD = −8.63, 95% CI = −19.94 to −2.68, p = 0.135, Supplementary Figure S2A ).

also in 111,027 other papers